Allstate Corp Increases Stake in Edwards Lifesciences Corporation $EW

Allstate Corp lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 106.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 43,601 shares of the medical research company’s stock after purchasing an additional 22,511 shares during the quarter. Allstate Corp’s holdings in Edwards Lifesciences were worth $3,717,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of EW. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. raised its position in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

EW opened at $86.55 on Thursday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $49.83 billion, a PE ratio of 46.04, a P/E/G ratio of 2.19 and a beta of 0.87. The firm has a 50 day moving average of $81.62 and a two-hundred day moving average of $82.97. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $88.28.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Evercore reissued an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Barclays reissued an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. BTIG Research raised their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $95.65.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,829 shares of company stock valued at $8,799,770 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.